Literature DB >> 3694493

Competition between two enzymes for substrate removal in liver: modulating effects due to substrate recruitment of hepatocyte activity.

M E Morris1, K S Pang.   

Abstract

Modulating effects of competing pathways, exemplified by sulfation (high affinity-low capacity) and glucuronidation (low affinity-high capacity), on drug disappearance and metabolite formation were investigated in a simulation study. The phenomenon of substrate recruitment of hepatocyte activity in drug removal and metabolite formation was shown with respect to inlet substrate concentration, and drug processing from inlet to outlet by enzyme systems localized differentially along the sinusoidal flow path in liver. Three enzymic distribution models: (A) sulfation and glucuronidation evenly distributed in liver, (b) sulfation occurring exclusively in the first half of the liver and glucuronidation in the second half, and (C) glucuronidation solely in the first half and sulfation in the second half, were described. The influence of Km and Vmax of the competing pathway, including enzyme induction (increase in Vmax), on any given pathway was also explored. Competing pathways exert their effects on other given pathways by modulating intrahepatic drug concentration from the inlet to outlet of the liver. When a competing pathway is similarly distributed or is at an anterior location to another pathway, the former pathway effectively reduces intrahepatic drug concentrations which reach downstream hepatocytes for recruitment of activity. For example, when glucuronidation activity is anterior to sulfation activity (defined with respect to flow direction), sulfation is without an effect on glucuronidation, but glucuronidation exerts a maximal influence over sulfation rates (Model C). When glucuronidation is in direct competition with sulfation (Model A) or is posteriorly distributed to sulfation (Model B), saturation of the high-affinity sulfation pathway leads to greater fluxes of substrate available downstream for glucuronidation. This results in an apparent compensatory increase in glucuronidation with reduced sulfation capacity, which occurs at input concentrations greater than the Km for sulfation but less than the Km for glucuronidation. This compensation pattern is more prominent for highly extracted compounds where both sulfation and glucuronidation are effective pathways in drug removal, and where large intrahepatic drug concentration gradients are expected. Since the physiologic description of intrahepatic drug concentration is often described by a concentration gradient from the inlet to outlet of the liver, the logarithmic average concentration has been used to estimate the mean liver concentration in the determination of kinetic constants for enzymic reactions.(ABSTRACT TRUNCATED AT 400 WORDS)

Mesh:

Substances:

Year:  1987        PMID: 3694493     DOI: 10.1007/bf01061758

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  36 in total

1.  The isolation of hormone-sensitive rat hepatocytes by a modified enzymatic technique.

Authors:  R N Zahlten; F W Stratman
Journal:  Arch Biochem Biophys       Date:  1974-08       Impact factor: 4.013

2.  Capillary exchange modeling. Barrier-limited and flow-limited distribution.

Authors:  C A Goresky; W H Ziegler; G G Bach
Journal:  Circ Res       Date:  1970-11       Impact factor: 17.367

3.  Effect of diffusional barriers on drug and metabolite kinetics.

Authors:  I A de Lannoy; K S Pang
Journal:  Drug Metab Dispos       Date:  1987 Jan-Feb       Impact factor: 3.922

Review 4.  Functional implications of liver cell heterogeneity.

Authors:  J J Gumucio; D L Miller
Journal:  Gastroenterology       Date:  1981-02       Impact factor: 22.682

5.  UDP glucuronyltransferase and phenolsulfotransferase in vivo and in vitro. Conjugation of harmol and harmalol.

Authors:  G J Mulder; A H Hagedoorn
Journal:  Biochem Pharmacol       Date:  1974-08       Impact factor: 5.858

6.  Aberrant Pharmacokinetics of harmol in the perfused rat liver preparation: sulfate and glucuronide conjugations.

Authors:  K S Pang; H Koster; I C Halsema; E Scholtens; G J Mulder
Journal:  J Pharmacol Exp Ther       Date:  1981-10       Impact factor: 4.030

7.  Dose- and time-dependent elimination of acetaminophen in rats: pharmacokinetic implications of cosubstrate depletion.

Authors:  R E Galinsky; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1981-10       Impact factor: 4.030

8.  Glucuronidation of 7-hydroxycoumarin in periportal and pericentral regions of the liver lobule.

Authors:  J G Conway; F C Kauffman; T Tsukada; R G Thurman
Journal:  Mol Pharmacol       Date:  1984-05       Impact factor: 4.436

9.  Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats.

Authors:  N Watari; M Iwai; N Kaneniwa
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

10.  Glucuronidation and sulfation of p-nitrophenol in isolated rat hepatocyte subpopulations. Effects of phenobarbital and 3-methylcholanthrene pretreatment.

Authors:  K Tonda; M Hirata
Journal:  Chem Biol Interact       Date:  1983-12       Impact factor: 5.192

View more
  10 in total

1.  Hepatic conjugation/deconjugation cycling pathways. Computer simulations examining the effect of Michaelis-Menten parameters, enzyme distribution patterns, and a diffusional barrier on metabolite disposition.

Authors:  S B Hansel; M E Morris
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

2.  Organ clearance concepts: new perspectives on old principles.

Authors:  G L Sirianni; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

3.  Membrane transport in hepatic clearance of drugs. II: Zonal distribution patterns of concentration-dependent transport and elimination processes.

Authors:  Y Kwon; M E Morris
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

4.  Upregulation of UGT2B4 Expression by 3'-Phosphoadenosine-5'-Phosphosulfate Synthase Knockdown: Implications for Coordinated Control of Bile Acid Conjugation.

Authors:  Kathleen G Barrett; Hailin Fang; Daniela Cukovic; Alan A Dombkowski; Thomas A Kocarek; Melissa Runge-Morris
Journal:  Drug Metab Dispos       Date:  2015-05-06       Impact factor: 3.922

5.  Hepatic modeling of metabolite kinetics in sequential and parallel pathways: salicylamide and gentisamide metabolism in perfused rat liver.

Authors:  X Xu; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1989-12

6.  Concentration-dependent metabolism of diazepam in mouse liver.

Authors:  M V St-Pierre; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1995-06

7.  Disposition of the Emerging Brominated Flame Retardant, 2-Ethylhexyl 2,3,4,5-Tetrabromobenzoate, in Female SD Rats and Male B6C3F1 Mice: Effects of Dose, Route, and Repeated Administration.

Authors:  Gabriel A Knudsen; J Michael Sanders; Linda S Birnbaum
Journal:  Toxicol Sci       Date:  2016-09-09       Impact factor: 4.849

8.  Nonlinear protein binding and enzyme heterogeneity: effects on hepatic drug removal.

Authors:  X Xu; P Selick; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

9.  Competing pathways in drug metabolism. II. An identical, anterior enzymic distribution for 2- and 5-sulfoconjugation and a posterior localization for 5-glucuronidation of gentisamide in the rat liver.

Authors:  M E Morris; V Yuen; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1988-12

Review 10.  Mechanistic considerations in benzene physiological model development.

Authors:  M A Medinsky; E M Kenyon; M J Seaton; P M Schlosser
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.